activator inhibitor-1 (PAI-1), encoded by SERPINE1, is a specific inhibitory member of plasminogen
activation (PA) system. Except for its key role in acute thrombotic events, PAI-1 was also expected to prevent cancer invasion and metastasis through its inhibition of urokinase-type plasminogen
activator, which was demonstrated to be involved in malignant dissemination. Indeed, there were some published articles showing this metastasis inhibitory effect.,, However, more articles suggested its pro-oncogenic roles.,,,,, In PC/PDAC, different in vitro and in vivo experiments also got inconsistent, even opposite results.,, However, those for its prognostic significance in PDAC seem to be more consistent.
Stroke in a young adult with familial plasminogen
Ten years after publishing the article "Thrombolytic Alphabet Soup: A Recipe for Disaster," the Institute for Safe Medication Practices recommended that the abbreviation "t-PA" or "TPA" for tissue plasminogen
activator not be used when referring to alteplase, including verbal or written orders.
On the other hand, uncontrolled plasminogen
activation contributes to many pathological processes, e.g.
This system comprises a few proteins that by acting in sequence lead to the conversion of zymogenic plasminogen
into its active enzymatic form, plasmin.
Biopharmaceutical company Prometic Life Sciences Inc (TSX:PLI) (OTCQX:PFSCF) reported on Monday the receipt of US Food and Drug Administration (FDA) orphan drug designation status for Plasminogen
(Ryplazim) for the treatment of idiopathic pulmonary fibrosis (IPF).
Prometic has previously reported data from this pivotal Phase 2/3 trial, which showed that Ryplazym treatment consistently replaced and maintained the plasminogen
concentration at an appropriate level and that it resolved all lesions in all 10 patients treated for 12 weeks.
Though limited by a smaller number of postimplementation cases and lack of 3-month poststroke functional outcome data, the findings suggest that 24/7 in-hospital availability of a neurologist improves door to intravenous tissue plasminogen
activator treatment times and in-hospital stroke mortality, Dr.
replacement therapy has been granted Orphan Drug and Fast Track Designations by the FDA.
Maggiorini, "Soluble urokinase-type plasminogen
activator receptor plasma concentration may predict susceptibility to high altitude pulmonary edema," Mediators of Inflammation, vol.
Hirakata, "Subretinal injection of recombinant tissue plasminogen
activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm," Graefes Archive for Clinical and Experimental Ophthalmology, vol.
Fibrinolysis is an important process in which fibrin is degraded by plasmin, which is activated by plasminogen
activator [1-4], leading to thrombolysis.